Skip to main content

Table 1 Characteristics of the participants categorized by changes of P50 of WC and weight loss of the participants

From: Changes in lysophospholipids and liver status after weight loss: the RESMENA study

 

All subjects

 

Δ Waist circumference (cm)

Δ Weight (kg)

n = 33

Baseline

6-months

P

< P50

≥ P50

< P50

≥ P50

Δ Anthropometry

 Weight (kg)

100.1 (9)

91.2 (19)

< 0.001

−6.1 (2)

− 11.2 (4)

−5.0 (2)

− 12.3 (33)

 BMI (kg/m2)

34.8 (4)

31.7 (5)

< 0.001

− 2.2 (1)

−3.9 (1)*

− 1.8 (0.9)*

−4.4 (1)*

 WC (cm)

110 (13)

102 (14)

< 0.001

−4.8 (2)

− 12.3 (3)

−5.6 (3.5)*

− 11.5 (4)*

 % TFM

37 (10)

31 (9)

< 0.001

−4.5 (3)

−8.6 (3)*

−4.0 (2)

−9.1 (3)

 VAT (kg)

3.1 (1.7)

2.2 (1)

< 0.001

− 0.8 (0.9)

− 0.9 (1)

− 0.8 (0.9)

− 0.9 (1)

Δ General biochemistry

 Glucose (mg/dl)

121.5 (37)

117.0 (32)

0.118

−1.2 (13)

−7.6 (18)

−2.4 (9)

−6.4 (20)

 Homa-IR

4.4 (3)

2.5 (3)

< 0.001

−1.7 (2)

−1.8 (15)

− 1.7 (2)

−1.8 (1)

 TC (mg/dl)

379 (144)

272 (106)

0.001

−55.3 (154)

− 155.1 (172)

−70.0 (24)

− 141.3 (199)

 HDL (mg/dl)

46.5 (10)

49.0 (10)

0.069

2.8 (7)

2.0 (7)

4.7 (6)

0.07 (8)

 LDL (mg/dl)

136.0 (44)

167.3 (38)

0.001

46.6 (37)

14.0 (57)

43.8 (35)

17.7 (60)

 TG (mg/dl)

198.6 (120)

160.4 (116)

0.003

−16.4 (74)

−61.2 (59)

−28.5 (75)

−48.3 (64)

 TyG -index

9.1 (0.7)

8.9 (0.7)

< 0.001

−0.1 (0.3)

−0.3 (0.3)

−0.2 (0.3)

− 0.3 (0.3)

 SBP (mmHg)

153.3 (21)

140.7 (15)

0.003

−12.9 (20)

−12.1 (24)

−7.1 (21)

− 18.3 (23)

 DBP(mmHg)

84.4 (9)

79.4 (10)

0.022

−5.7 (9)

−4.0 (14)

−2.6 (10)

−7.2 (12)

Δ Hepatic status

 ALT (U/L)

34.9 (21)

23.1 (8)

0.001

−9.3 (15)

−14.2 (23)

− 13.0 (15)

− 10.3 (24)

 AST (U/L)

26.0 (11)

21.3 (5)

0.027

−2.1 (9)

−7.5 (13)

−5.3 (10)

−4.1 (13)

 GGT (U/L)

45.6 (32)

31.6 (19)

< 0.001

−13.1 (18)

−14.8 (17)

− 15.8 (19)

−11.9 (16)

 FLI

84.7 (18)

64.9 (27)

< 0.001

−10.1 (11)

−30.0 (16)*

− 10.6 (10)

−29.4 (17)*

 M30 (U/L)

199.9 (14)

123.9 (48)

0.002

−57.6 (110)

−45.4 (145)

−82.5 (152)

−69.0 (106)

 M65 (U/L)

325.7 (206)

213.7 (72)

0.002

−79.6 (149)

− 146.2 (241)

−116.5 (215)

− 107.0 (187)

 HSI

47.7 (6)

42.6 (6)

< 0.001

−4.2 (3)

−5.9 (3)

− 4.1 (36)

−6.0 (3)

 VAI

3.2 (2)

2.4 (2)

0.008

−0.5 (1)

−1.2 (1)

−0.7 (1)

−0.9 (1)

 NAFLD_LFS

1.8 (2)

0.2 (2)

< 0.001

−1.2 (1)

−1.9 (1)

− 1.5 (1)

−1.6 (2)

 BARD score

2.7 (1)

2.9 (1)

0.587

0.5 (1)

−0.3 (1)

0.4 (1)

−0.1 (1)

 BAAT score

2.1 (0.7)

1.7 (0.6)

< 0.001

−0.2 (0.4)

−0.6 (0.6)

− 0.3 (0.4)

−0.5 (0.6)

Δ Inflammatory status

 hsCRP (mg/l)

4.6 (6)

2.6 (3)

0.035

−2.2 (6)

−1.8 (3)

−1.2 (2)

−2.9 (7)

  1. (mean ± SD). Pared and independent t tests were carried out. *p < 0.05, comparison within each group (<WC/weight P50 vs ≥ WC/weight P50). P-values were adjusted using an ancova test adjusting for sex and gender
  2. BMI Body Mass Index, WC Waist Circumference, TFM Total Fat Mass, VAT Visceral Adipose Tissue, SBP Systolic Blood Pressure, HOMA-IR Insulin Resistance HOMA index, DBP Diastolic Blood Pressure, TC Total Cholesterol, HDL High Density Lipoprotein, LDL Low Density Lipoprotein, TyG triglycerides/glucose ratio, TG Triglycerides, ALT Alanine Transaminase, AST Aspartate Transaminase, GGT Gamma-glutamyl transferase, HSI hepatic steatosis index, VAI Visceral adipose index, NAFLD_LFS Fatty liver disease, BARD score; BAAT score and hsCRP his sensitivy C-reactive protein
Back to article page

Nutrition & Metabolism

ISSN: 1743-7075

Contact us